Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presentedDosing of the final cohort in the first in human study has ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...

-- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating ...

On Wednesday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that the final patient completed the last dose in the pharmacokinetics study of AD04 for Alcohol Use Disorder (AUD) in heavy drinking ...

Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned ...

BOSTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for ...

Data supports the novel Trans-Arterial Micro-Perfusion (TAMP TM) therapy platform for targeted chemotherapy delivery for the potential to minimize a therapy’s toxicities versus systemic intravenous ...

Serplulimab achieves pharmacodynamic saturation, supporting its current clinical use without the need for higher doses. The ASTRUM-005 trial established serplulimab as the PD-1 inhibitor with the ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight ...

No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET inhibitor All hematological parameters, including ...